De novo lipogenesis enzyme abundance

1. Trametinib decreases de novo lipogenesis enzyme abundance in mice.

   “The same pattern of changes in the de novo lipogenesis enzymes can be produced, in cultured cells or in intact mice, by trametinib”

   Animals

   The lifespan-extending MEK1 inhibitor trametinib promotes regulation of de novo lipogenesis enzymes by chaperone-mediated autophagy

   Frontiers in aging·25 Jun 2025

More on Trametinib

1. Autophagy is required for de novo lipogenesis enzyme abundance in mouse cells.

   “The trametinib effect on DNL enzymes is, unexpectedly, not related to transcriptional changes, but depends on selective protein degradation through chaperone-mediated autophagy.”

   Cellsrequired for the trametinib-induced decrease

   The lifespan-extending MEK1 inhibitor trametinib promotes regulation of de novo lipogenesis enzymes by chaperone-mediated autophagy

   Frontiers in aging·25 Jun 2025

More on Autophagy